A Powder that Cleanses the Blood, Liver, and Gut

Why It Matters

Resistant starches offer a scalable, diet‑based approach to lower harmful BCAAs and liver fat, presenting both a therapeutic option for metabolic disease and a growth niche for nutraceutical companies.

Key Takeaways

• Resistant starches lower blood branched‑chain amino acids levels
• Reduced BCAAs correlate with decreased liver fat accumulation
• Clinical trials used ~40 g resistant starch per day
• Primary natural source: unripe or green bananas for consumption
• BCAAs remain beneficial unless metabolic dysfunction is present

Summary

The video spotlights resistant starches—a class of indigestible carbohydrates—as a therapeutic “powder” that can cleanse blood, liver, and gut by modulating the gut microbiome.

When consumed, resistant starch bypasses upper‑intestinal digestion and ferments in the colon, fostering a microbiome that produces fewer branched‑chain amino acids (BCAAs). Elevated BCAAs have been linked to hepatic steatosis; multiple trials showed that a daily intake of roughly 40 g of resistant starch reduces microbial BCAA output, lowers circulating BCAA levels, and consequently diminishes liver fat.

The presenter cites unripe or green bananas as the only common food delivering sufficient resistant starch, while commercial powders can supply 60‑70 g depending on purity. He also addresses a frequent query, clarifying that BCAAs are not universally harmful—only in the context of metabolic dysfunction do they become a risk factor.

For investors and health‑focused consumers, the data suggest a market opportunity for resistant‑starch supplements aimed at metabolic‑syndrome patients, while clinicians may consider dietary recommendations as a low‑cost adjunct to liver‑fat reduction strategies.

Original Description

Higher blood BCAAs are consistently linked to higher liver fat. 🧬

Leucine, valine, and isoleucine are associated with a greater risk of non-alcoholic fatty liver disease, and people with more BCAAs circulating in their bloodstream tend to have more fat stored in their livers.

This relationship depends on consumption, production, and impaired clearance. In insulin resistance and other metabolic problems, high BCAAs are less about one high-protein meal and more about a body that’s struggling to handle nutrients properly.

Some gut bacteria also produce BCAAs. In people with fatty liver disease, pathways involved in BCAA production are more active in those with more liver fat.

Resistant starch resists digestion in the small intestine, reaches the colon, and becomes food for gut bacteria.

In studies, resistant starch reduced BCAA production in the colon, lowered blood levels of valine, leucine, and isoleucine over time, and led to a meaningful reduction in liver fat. 🥄

Effective intakes typically fall around 40 grams per day. Common sources include green banana powder, high-amylose maize starch, and potato starch.

Main Points:

Higher blood BCAAs are associated with greater liver fat and higher fatty liver risk. Certain gut bacteria produce BCAAs, which contribute to higher blood levels. Resistant starch reduces BCAA production in the colon, lowers blood BCAAs, and can reduce liver fat over time.

References:

Ni Y, et al. Cell Metab. 2023;35(9):1530-1547. doi:10.1016/j.cmet.2023.08.002

Long X, et al. Cell Metab. 2025;37:2342-2361. doi:10.1016/j.cmet.2025.10.017

Lo EKK, et al. Biomedicines. 2022;10(6):1444. doi:10.3390/biomedicines10061444

Mansoori S, et al. Obes Rev. 2025;26(2):e13856. doi:10.1111/obr.13856